$85 Million Premises Liability Verdict | Here goes a short description of the case (maybe the title) and a link to read more (optional)

FDA warns Pfizer Inc. of “significant violations” at a manufacturing plant

Hospira

pfizer logoLast month, the United States Food and Drug Administration sent a letter to pharmaceutiucal company, Pfizer, Inc., warning of “significant violations” at a Hospira manufacturing plant.

Pfizer acquired Hospira in a $17 billion deal in 2015. An inspection was conducted from May to June of 2015 at a McPherson, Kansas Hospira drug plant, and the inspection cited “significant violations of current good manufacturing practice.” Further observations included the potential for contamination of sterile products, failure to appropriately respond to contaminated drug products within the facility, and “significant loss of control in [the] manufacturing process and…a severe risk of harm to patients.”

The FDA’s letter also stated that similar and additional violations were found at a number of other Hospira facilities. The FDA wrote to Pfizer that, “These repeated failures at multiple sites demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate.”

A Pfizer spokeswoman claims that the FDA’s concerns are not related to any Pfizer products currently on the market. “Patient safety is of primary importance to Pfizer, and the company is committed to ensuring the safety and quality of our medicines,” she said. These claims of committment to to safety and quality appear to be false, however, considering that Pfizer received complaints from the FDA on three separate dates (Dec 2015, Feb 2016, April 2016) regarding contamination of an injectable antibiotic called vancomycin. It wasn’t until May 2016, over four months after receiving the first complaint, that the company finally recalled the contaminated drug.

New Jersey and Philadelphia Personal Injury Attorneys

The team of Philadelphia personal injury attorneys at Messa & Associates is highly experienced in handling dangerous medical malpractice, drug, and medical device cases. The firm has earned multiple seven-, eight-, and nine-figure verdicts and settlements for clients injured by defective drugs, including over $14 million in Topamax mass tort cases in Philadelphia for victims of Topamax-related birth defects.

Messa & Associates is armed with the right attorneys and the necessary connections to successfully litigate defective drug and medical device claims. If you or a loved one has become infected by the disease associated with drug tampering at Shore Memorial, contact an attorney from Messa & Associates. Call 1-877-MessaLaw for a free consultation or submit an online inquiry for a free case evaluation.

About the Author

Joe Messa

Joe MessaJoe Messa is the founder of Messa & Associates, a results-oriented personal injury law firm comprised of New Jersey and Philadelphia attorneys who specialize in medical malpractice, product liability, catastrophic injury, motor vehicle accidents, brain injury, birth injury, and burns, fires, and explosions. Messa & Associates holds a distinguished record of multi-million dollar verdicts and settlements for catastrophically injured clients, including but certainly not limited to: a $120 million Products Liablity settlement, an $85 million Premises Liability verdict, a $35 million Work Injury settlement, a $28.7 million Motor Vehicle Accident verdict, and a $16.5 million Medical Malpractice verdict.View all posts by Joe Messa →

Leave a Reply

Philadelphia | Downingtown | Conshohocken | Cherry Hill | Collingswood | Linwood | Roselle